Head and neck cancer, excluding thyroid
Invited Discussant 1045PD, 1046PD and 1047PD
Date
09 Sep 2017Session
Head and neck cancer, excluding thyroidPresenters
Joel GuigayAuthors
J. GuigayAuthor affiliations
- -, Centre Antoine Lacassagne, 6100 - Nice/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3044 - An Open-label, Multicohort, Phase 1/2 Study in Patients With Virus-Associated Cancers (CheckMate 358): Safety and Efficacy of Neoadjuvant Nivolumab in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Presenter: Robert Ferris
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
Head and neck cancer: Invited Discussant LBA46, 1048PD and 1049PD
Presenter: Amanda Psyrri
Session: Head and neck cancer, excluding thyroid
Resources:
Slides
Webcast
2417 - First line Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer: a randomized phase IIb trial
Presenter: Paolo Bossi
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
Head and neck cancer: Invited Discussant LBA47, 1050PD and 1051PD
Presenter: Sjoukje Oosting
Session: Head and neck cancer, excluding thyroid
Resources:
Slides
Webcast
Invited Discussant 1052PD, 1053PD and 1054PD
Presenter: Jean Bourhis
Session: Head and neck cancer, excluding thyroid
Resources:
Slides
Webcast
2324 - Treatment Beyond Progression With Nivolumab in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Phase 3 Checkmate 141 Study: A Biomarker Analysis and Updated Clinical Outcomes
Presenter: Robert Haddad
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
Slides
Webcast
4767 - Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
Presenter: Dan Zandberg
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
4202 - Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results
Presenter: Rastislav Bahleda
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
1666 - Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
Presenter: Ezra Cohen
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
Slides
Webcast
Head and neck cancer: Invited Discussant LBA45 and 1043O
Presenter: Sandrine Faivre
Session: Head and neck cancer, excluding thyroid
Resources:
Slides
Webcast